SA519402010B1 - طرق محسنة لتعزيز إنتاجية الأجسام المضادة في مزرعة خلايا الثدييات والحد من حدوت تكتل أثناء العمليات الفرعية والصياغة وصياغات من الأجسام المضادة مستقرة يتم الحصول عليها باستخدام هذه الطرق - Google Patents

طرق محسنة لتعزيز إنتاجية الأجسام المضادة في مزرعة خلايا الثدييات والحد من حدوت تكتل أثناء العمليات الفرعية والصياغة وصياغات من الأجسام المضادة مستقرة يتم الحصول عليها باستخدام هذه الطرق

Info

Publication number
SA519402010B1
SA519402010B1 SA519402010A SA519402010A SA519402010B1 SA 519402010 B1 SA519402010 B1 SA 519402010B1 SA 519402010 A SA519402010 A SA 519402010A SA 519402010 A SA519402010 A SA 519402010A SA 519402010 B1 SA519402010 B1 SA 519402010B1
Authority
SA
Saudi Arabia
Prior art keywords
methods
cell culture
formulation
subprocesses
antibody
Prior art date
Application number
SA519402010A
Other languages
English (en)
Inventor
نيخيل داتاتاري أفالسكار
ريدي سرينيفاز ريدي بيدي
سامبهاجي شنكر بيسال
راجيف مهالاساكانت دهيري
ديجامبر شاهار سينغ
بانكاج سينغ شوهان
لينا رافندرا يوليكار
Original Assignee
سيروم انستيتيوت أُف إنديا برايفت ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by سيروم انستيتيوت أُف إنديا برايفت ليمتد filed Critical سيروم انستيتيوت أُف إنديا برايفت ليمتد
Publication of SA519402010B1 publication Critical patent/SA519402010B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتعلق الاختراع الحالي بمنصة لتصنيع فعالة لتصنيع الجسم المضاد antibody والصياغة التي تُقدم 1) عملية استزراع الخلية cell culture process مع استراتيجية تغذية مُحسنة تتسبب في عيار مرتفع للجسم المضاد ما بين 2 جم/ لتر إلى 5 جم/ لتر؛ 2) عملية تنقية مُحسنة تُظهر نسبة الاستخلاص الأمثل، محتوى نقاء المونومير المرتفع، تكوين أقل تكتل/ جسيمات، أقل مستويات للشوائب؛ 3) سوائل مناسبة عالية التركيز تم صياغتها بأسمولالية Osmolality أمثل ولزوجة منخفضة عبر انحرافات درجة الحرارة المختلفة وخلوه من التكتل. تتضمن الأجسام المضادة antibodies المٌفضلة جسم مضاد antibody أحادي النسيلة IgG1 خاص بالقمة اللاصقة لفيروس حمى الضنك Dengue في نطاق III الخاص ببروتين E والجسم المضاد antibody أحادي النسيلة IgG1 الخاص بالجليكوبروتين G لسطح فيروس السعار rabies virus. الشكل 1.
SA519402010A 2016-12-23 2019-06-20 طرق محسنة لتعزيز إنتاجية الأجسام المضادة في مزرعة خلايا الثدييات والحد من حدوت تكتل أثناء العمليات الفرعية والصياغة وصياغات من الأجسام المضادة مستقرة يتم الحصول عليها باستخدام هذه الطرق SA519402010B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621044139 2016-12-23
PCT/IB2017/058194 WO2018116198A1 (en) 2016-12-23 2017-12-20 Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof

Publications (1)

Publication Number Publication Date
SA519402010B1 true SA519402010B1 (ar) 2022-09-20

Family

ID=61054429

Family Applications (1)

Application Number Title Priority Date Filing Date
SA519402010A SA519402010B1 (ar) 2016-12-23 2019-06-20 طرق محسنة لتعزيز إنتاجية الأجسام المضادة في مزرعة خلايا الثدييات والحد من حدوت تكتل أثناء العمليات الفرعية والصياغة وصياغات من الأجسام المضادة مستقرة يتم الحصول عليها باستخدام هذه الطرق

Country Status (27)

Country Link
US (2) US20200131251A1 (ar)
EP (1) EP3559027B1 (ar)
JP (1) JP7265477B6 (ar)
KR (1) KR102595080B1 (ar)
CN (1) CN110337445B (ar)
AR (1) AR110584A1 (ar)
AU (1) AU2017380842B2 (ar)
BR (1) BR112019011900A2 (ar)
CO (1) CO2019006289A2 (ar)
CR (1) CR20190291A (ar)
DK (1) DK3559027T3 (ar)
EA (1) EA201900326A1 (ar)
ES (1) ES2926028T3 (ar)
GE (2) GEP20237513B (ar)
HR (1) HRP20221071T1 (ar)
MX (1) MX2019007564A (ar)
MY (1) MY197200A (ar)
PE (1) PE20191436A1 (ar)
PH (1) PH12019501472A1 (ar)
PT (1) PT3559027T (ar)
RS (1) RS63533B1 (ar)
SA (1) SA519402010B1 (ar)
TW (2) TWI830692B (ar)
UA (1) UA128200C2 (ar)
UY (1) UY37547A (ar)
WO (1) WO2018116198A1 (ar)
ZA (1) ZA201904046B (ar)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
KR102585976B1 (ko) 2016-08-17 2023-10-05 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
WO2019099921A2 (en) 2017-11-17 2019-05-23 Amgen Inc. Vegfr-fc fusion protein formulations
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
RU2764740C1 (ru) 2018-08-09 2022-01-20 Бейцзин Уиздомаб Байотекнолоджи Ко., Лтд Биспецифическое антитело против вируса бешенства и его применение
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
WO2020071876A1 (ko) * 2018-10-04 2020-04-09 삼성바이오에피스 주식회사 점도가 감소된 고농도 트라스투주맙 또는 이의 항원 결합 단편 안정화 제제
MX2021004356A (es) * 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
WO2020088180A1 (en) * 2018-11-02 2020-05-07 Wuxi Biologics (Shanghai) Co., Ltd. Cell culture process by intensified perfusion with continuous harvest and without cell bleeding
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
CN109576212B (zh) * 2018-12-14 2021-06-22 杭州奕安济世生物药业有限公司 高密度接种培养中种子细胞的培养方法及其应用
CN111349142B (zh) * 2018-12-20 2024-09-13 上海百迈博制药有限公司 一种蛋白质的纯化方法
MX2021008983A (es) * 2019-01-30 2021-09-08 Amgen Inc Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
CN112011514B (zh) * 2019-05-31 2024-12-24 百济神州(苏州)生物科技有限公司 提高抗体adcc活性的细胞培养工艺
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
US20220280643A1 (en) * 2019-07-29 2022-09-08 Mark White Anti-pvrig antibodies formulations and uses thereof
UY38819A (es) * 2019-08-01 2021-02-26 Gennova Biopharmaceuticals Ltd Composición oftálmica de bevacizumab
CA3154726A1 (en) * 2019-09-23 2021-04-01 Merck Sharp & Dohme Corp. Methods and compositions comprising an anti-ctla4 monoclonal antibody with reduced host cell proteins and increased polysorbate-80 stability
WO2021064079A1 (en) * 2019-10-04 2021-04-08 Merck Patent Gmbh Purification of proteins and viral inactivation
WO2021091605A1 (en) * 2019-11-04 2021-05-14 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
IL309560B2 (en) * 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
WO2021164107A1 (zh) * 2020-02-19 2021-08-26 中国科学技术大学 Il-6受体抗体的新用途
KR102370142B1 (ko) * 2020-03-23 2022-03-04 프레스티지바이오로직스 주식회사 항체 의약품 제조를 위한 배양 및 정제 공정의 하이브리드 시스템
CN113563469A (zh) * 2020-04-28 2021-10-29 江苏中新医药有限公司 高回收率纯化阿达木单抗的方法
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
IL298989A (en) * 2020-07-03 2023-02-01 CSL Innovation Pty Ltd High concentration promotion of factor XII antigen binding proteins
CN114984203A (zh) * 2021-03-01 2022-09-02 正大天晴药业集团股份有限公司 包含靶向PD-L1和TGF-β的融合蛋白的药物组合物
CN113274494B (zh) * 2021-06-07 2022-09-20 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的重组全人源单克隆抗体的液体制剂
WO2023043658A2 (en) * 2021-09-14 2023-03-23 Caelum Biosciences Method of treating multiple myeloma
KR102682066B1 (ko) * 2021-10-12 2024-07-05 프레스티지바이오로직스 주식회사 항체 집단의 제조 방법
US20250243241A1 (en) * 2022-04-04 2025-07-31 Intas Pharmaceuticals Ltd. Multi-component buffer system for purification of antibodies
IL328394A (en) * 2023-11-23 2026-07-01 Sun Pharmaceutical Ind Ltd Methods for producing recombinant proteins
WO2026035859A1 (en) * 2024-08-06 2026-02-12 Trustees Of Tufts College Use of engineered multicellular organisms for screening antiaging and pro-regenerative compositions
CN120518757B (zh) * 2025-07-23 2025-09-23 中国人民解放军军事科学院军事医学研究院 一种聚乙二醇化多价抗西尼罗病毒单链抗体

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US20060257972A1 (en) 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
DK1851315T3 (en) * 2005-02-02 2014-03-24 Univ Massachusetts HUMAN ANTIBODIES AGAINST RABIES AND APPLICATIONS THEREOF
TW201516149A (zh) 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
CA2932207A1 (en) 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
WO2011028962A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
US20120238730A1 (en) * 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
UY34054A (es) 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
US20140288278A1 (en) 2011-10-31 2014-09-25 Joseph Nti-Gyabaah Chromatography process for resolving heterogeneous antibody aggregates
AU2013299986B2 (en) 2012-08-07 2018-05-17 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2014102814A1 (en) 2012-12-31 2014-07-03 Intas Biopharmaceuticals Limited Process for the purification of fc fusion proteins
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US10654933B2 (en) 2013-12-27 2020-05-19 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
JP6764348B2 (ja) 2014-02-11 2020-09-30 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子およびその使用
AU2015217149B2 (en) 2014-02-11 2020-09-10 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
WO2015125820A1 (ja) * 2014-02-18 2015-08-27 サヴィッド・セラピューティックス株式会社 ビオチン改変体、ストレプトアビジン変異体およびそれらの利用
ES2949173T3 (es) 2014-09-15 2023-09-26 Hoffmann La Roche Formulaciones de anticuerpo
US11267899B2 (en) * 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
CA2995109A1 (en) 2015-08-13 2017-02-16 University Of Massachusetts Human antibodies against rabies and uses thereof
ZA201604024B (en) * 2015-09-26 2017-08-30 Serum Institute Of India Pvt Ltd Improved feeding strategies and purification processes for monoclonal antibody production
EP3433274A1 (en) 2016-03-25 2019-01-30 Visterra, Inc. Formulation of antibody molecules to dengue virus
TWI766876B (zh) * 2016-08-03 2022-06-11 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法

Also Published As

Publication number Publication date
UA128200C2 (uk) 2024-05-08
TWI830692B (zh) 2024-02-01
CO2019006289A2 (es) 2019-06-28
MY197200A (en) 2023-05-31
EA201900326A1 (ru) 2019-11-29
CA3047530A1 (en) 2018-06-28
KR20190099269A (ko) 2019-08-26
WO2018116198A1 (en) 2018-06-28
AU2017380842B2 (en) 2025-01-23
HRP20221071T1 (hr) 2022-11-11
BR112019011900A2 (pt) 2019-11-26
US20240309073A1 (en) 2024-09-19
TW201829777A (zh) 2018-08-16
TW202413401A (zh) 2024-04-01
CN110337445A (zh) 2019-10-15
CN110337445B (zh) 2023-05-23
GEAP202315128A (en) 2023-02-10
CR20190291A (es) 2019-11-05
PE20191436A1 (es) 2019-10-14
ZA201904046B (en) 2022-02-23
AR110584A1 (es) 2019-04-10
AU2017380842A1 (en) 2019-07-11
EP3559027B1 (en) 2022-06-01
PH12019501472A1 (en) 2020-03-09
GEP20237513B (en) 2023-06-12
DK3559027T3 (da) 2022-09-05
EP3559027A1 (en) 2019-10-30
UY37547A (es) 2018-06-29
MX2019007564A (es) 2019-09-06
PT3559027T (pt) 2022-09-06
JP7265477B2 (ja) 2023-04-26
KR102595080B1 (ko) 2023-10-30
ES2926028T3 (es) 2022-10-21
US20200131251A1 (en) 2020-04-30
JP7265477B6 (ja) 2023-05-12
RS63533B1 (sr) 2022-09-30
JP2020501592A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
PH12019501472A1 (en) Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
ME03819B (me) Antitela za icos
PE20200839A1 (es) Anticuerpos anti-cd137
EP2522724A4 (en) POLYPEPTIDE MODIFYING METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
JP2015146822A5 (ar)
JP2019514383A5 (ar)
JP2015532096A5 (ar)
SA518391704B1 (ar) C5 أجسام مضادة لـ وطرق لاستخدامها
AR082171A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ngf
EA035160B9 (ru) Антитела к st2 и их применение
JP2016526385A (ja) モノクローナル抗体の改良された産生方法
AR100573A1 (es) Anticuerpos anti-il-17, un método para producirlos y utilizarlos
PH12018502354B1 (en) Anti-c5 antibodies and methods of use
HRP20211541T1 (hr) Anti-asic1 antitijela i njihove upotrebe
MA40929A (fr) Procédé de production d'anticorps à affinité élevée
RU2017126025A (ru) Селективное восстановление цистеиновых остатков в антителах против il-17
CN103898060B (zh) Hat半固体筛选培养基以及杂交瘤细胞的筛选方法
WO2018018613A1 (zh) 一种提高抗体纯度的细胞培养基和培养方法
EA202090350A1 (ru) Стабилизированные композиции антител и способы их получения
TH1901003862A (th) วิธีการที่ถูกปรับปรุงสำหรับการเสริมความสามารถในการผลิตแอนตี้บอดี้ในกระเพาะเลี้ยงเซลล์สัตว์เลี้ยงลูกด้วยนมและลดการจับก้อนระหว่างดาว์นสตรีม, กรรมวิธีการเตรียมสูตรและสารผสมตามสูตรของแอนตี้บอดี้ที่เสถียรที่ได้รับของสิ่งเหล่านี้
LT2005043A (en) Process for preparing monoclonal antibodies; hybridoma cell lines generated by this process and recombinant chimeric virus-like particles with inserted foreign protein fragments as immunogenes to generate hybridomas by this process
AR127270A1 (es) Formulación de anticuerpos anti-cd47
CN105601734A (zh) 一种从人外周血记忆性b淋巴细胞制备抗体的方法
JP2019528074A5 (ar)
Bae et al. Intracellular responses of antibody-producing H69K-NGD transfectoma subjected to hyperosmotic pressure